Organisation paid for research Program year 2025 Source: CMS Open Payments

Empire Clinical Research LLC

Neither a doctor nor a teaching hospital

Research payments

$3,222,064

998 payments

Through program year 2025, Empire Clinical Research LLC is reported as receiving $3,222,064 in research payments, across 998 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $423,597 48
2024 Research $202,666 17
2023 Research $942,752 260
2022 Research $949,949 596
2021 Research $338,897 35
2020 Research $124,538 11
2019 Research $239,665 31

Breakdown

Who paid Research payments · program years 2019–2025
  1. Pfizer Inc. $1,376,625 78 payments
  2. Moderna TX, Inc. $717,339 786 payments
  3. Novavax Inc $236,196 26 payments
  4. Amgen Inc. $204,717 4 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $169,291 5 payments
  6. Akebia Therapeutics Inc $164,340 8 payments
  7. AbbVie, Inc. $78,504 23 payments
  8. Lexicon Pharmaceuticals, Inc. $66,369 11 payments
  9. Evofem Biosciences, Inc. $65,250 26 payments
  10. Mylan Technologies Inc. $50,393 4 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3 Randomized Observerblinded Study to Evaluate the Efficacy Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Influenza Compared to Licensed Inactivated Influenza Vaccine in Healthy Adults 18 Years of Age Or Older $859,117 29 payments
  2. A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older $383,834 562 payments
  3. A Phase 3 Study to Evaluate the Efficacy Immunogenicity and Safety of Respiratory Syncytial Virus RSV Prefusion F Subunit Vaccine in Adults $356,391 31 payments
  4. A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) $190,381 12 payments
  5. A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older $176,531 194 payments
  6. A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARITIME-2) $158,096 3 payments
  7. Immunogenicity and Safety of Tetravalent Dengue Vaccine TDV Administered With a Yellow Fever Vaccine in Adults $148,439 2 payments
  8. M16-283 $78,504 23 payments
  9. A 16Week Phase 2B Randomized Doubleblind Placebocontrolled Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Pf06882961 Administration in Adults With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin Or Diet and Exercise $70,499 4 payments
  10. A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?50 Years of Age $67,238 9 payments
What the money was spent on Research payments · program years 2019–2025
  1. Other $148,439 2 payments
  2. Professional salary support $50,978 20 payments
  3. Patient care $12,000 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record